The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Meng, Jia ^a   Li, Yan ^b   Camarillo, Cynthia ^c   Yao, Yue ^a   Zhang, Yina ^a   Xu, Chun ^c   Jiang, Lihong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CURCUMIN; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN KINASE B; SUPEROXIDE DISMUTASE; VORINOSTAT;

AKT1 GENE; ALZHEIMER DISEASE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREBBP GENE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; EP300 GENE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DISTANCE; HISTONE ACETYLATION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PC12 CELL; PROTEIN PROTEIN INTERACTION; RAT; TRANSCRIPTION REGULATION; UPREGULATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; CELL SURVIVAL; CREB-BINDING PROTEIN; CURCUMIN; DISEASE PROGRESSION; DRUG SYNERGISM; E1A-ASSOCIATED P300 PROTEIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HISTONE DEACETYLASE INHIBITORS; NEURONS; NEUROPROTECTIVE AGENTS; NYLONS; OXIDATIVE STRESS; PC12 CELLS; PYRROLES; RATS;

EID: 84896998024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085570     Document Type: Article

References (42)

1. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430: 631-639. (Pubitemid 39061671)
2. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
3. Yamaguchi H, Ishiguro K, Uchida T, Takashima A, Lemere CA, et al. (1996) Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 92: 232-241. (Pubitemid 26278953)
4. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698-712.
5. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3: 77sr1.
6. Golde TE, Schneider LS, Koo EH (2011) Anti-Ab therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203-213.
7. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, et al. (2004) Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101: 2173-2178. (Pubitemid 38229034)
8. Korzus E (2010) Manipulating the brain with epigenetics. Nat Neurosci 13: 405-406.
9. Stilling RM, Fischer A (2011) The role of histone acetylation in age-associated memoryimpairment and Alzheimer's disease. Neurobiol Learn Mem 96: 19-26.
10. Xu K, Dai XL, Huang HC, Jiang ZF (2011) Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev 2011: 143269.
11. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, et al. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35: 870-880.
12. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552. (Pubitemid 47255934)
13. Rouaux C, Loeffler JP, Boutillier AL (2004) Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochem Pharmacol 68: 1157-1164. (Pubitemid 39094281)
14. Selvi BR, Cassel JC, Kundu TK, Boutillier AL (2010) Tuning acetylation levels with HAT activators: therapeutic strategy in neurodegenerative diseases. Biochim Biophys Acta 1799: 840-853.
15. Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27: 659-666.
16. Wang Y, Yin H, Wang L, Shuboy A, Lou J, et al. (2013) Curcumin as a potential treatment for Alzheimer's disease: a study of the effects of curcumin on hippocampal expression of glial fibrillary acidic protein. Am J Chin Med 41: 59-70.
17. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: Apractical and powerful approach to multiple testing. J Roy Statist Soc Ser 57: 289-300.
18. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, et al. (2010) BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 11: 91.
19. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
20. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250.
21. Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M (2008) Computing topological parameters of biological networks. Bioinformatics 24: 282-284.
22. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
23. Vlasblom J, Wu S, Pu S, Superina M, Liu G, et al. (2006) GenePro: a Cytoscape plug-in for advanced visualization and analysis of interaction networks. Bioinformatics 22: 2178-2179. (Pubitemid 44390917)
24. Vázquez de la Torre A, Junyent F, Folch J, Pelegrí C, Vilaplana J, et al. (2013) PI3 k/akt inhibition induces apoptosis through p38 activation in neurons. Pharmacol Res 70: 116-125.
25. Clark CM, Sheppard L, Fillenbaum GG, Galasko D, Morris JC, et al. (1999) Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 56: 857-862. (Pubitemid 29318912)
26. Lu X, Jain VV, Finn PW, Perkins DL (2007) Hubs in biological interaction networks exhibit low changes in expression in experimental asthma. Mol Syst Biol 3: 98.
27. Barabási AL, Oltvai ZN (2004) Network biology: understanding the cell's functional organization. Nat Rev Genet 5: 101-113. (Pubitemid 38160277)
28. Gon i J, Esteban FJ, de Mendizábal NV, Sepulcre J, Ardanza-Trevijano S, et al. (2008) A computational analysis of protein-protein interaction networks in neurodegenerative diseases. BMC Syst Biol 2: 52.
29. Lopez OL (2011) The growing burden of Alzheimer's disease. Am J Manag Care Suppl 13: S339-S345.
30. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 28: 111-128.
31. Bajda M, Guzior N, Ignasik M, Malawska B (2011) Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem 18: 4949-4975.
32. Patel L, Grossberg GT (2011) Combination therapy for Alzheimer's disease. Drugs Aging 28: 539-546.
33. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413: 739-743. (Pubitemid 33009952)
34. Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. Curr Drug Targets 12: 332-347.
35. Li S, Zhang B, Zhang N (2011) Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol 5 Suppl 1: S10.
36. Noorbakhsh F, Overall CM, Power C (2009) Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 32: 88-100.
37. Satoh J, Tabunoki H, Arima K (2009) Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Dis Markers 27: 239-252.
38. Jain S, Heutink P (2010) From single genes to gene networks: high-throughputhigh-content screening for neurological disease. Neuron 68: 207-217.
39. Liu R, Lei JX, Luo C, Lan X, Chi L, et al. (2012) Increased EID1 nuclear translocation impairs synaptic plasticity and memory function associated with pathogenesis of Alzheimer's disease. Neurobiol Dis 45: 902-912.
40. Sabbagh M, Cummings J (2011) Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol 11: 21.
41. Hegde AN, Upadhya SC (2011) Role of ubiquitin-proteasome-mediated proteolysis in nervous system disease. Biochim Biophys Acta 1809: 128-140.
42. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. (Pubitemid 46014485)